…and some to hold, avoid or sell

The Week - - Shares City -

4d pharma In­vestors Chron­i­cle

This ju­nior biotech is steadily pro­gress­ing with its IBS (ir­ri­ta­ble bowel) treat­ment. But it’s mov­ing into a cash-greedy trial phase for can­cer and asthma treat­ments and needs “fur­ther sig­nif­i­cant progress” to raise cap­i­tal. Sell. 365p.

In­ter­con­ti­nen­tal Ho­tels The Sun­day Times

Shares in the ho­tel op­er­a­tor leapt af­ter the Brexit vote, thanks to US rev­enues. But bumper div­i­dends have been funded by prop­erty sales. The group is now “as­set light” with de­te­ri­o­rat­ing rev­enues. Sell. £40.93.

Revo­lu­tion Bars Group The Daily Tele­graph

In May shares in the bar chain dropped on a profit warn­ing, but rose on an im­proved out­look and takeover in­ter­est. Now a ma­jor backer, Slater In­vest­ments, has sold, cit­ing a 4% pre­mium to a bid of­fer. Fol­low suit. Sell. 211.5p.

Stage­coach Group In­vestors Chron­i­cle

The bus and rail op­er­a­tor looks cheap, but Lon­don bus rev­enues are ex­pected to fall rapidly fol­low­ing the loss of TFL con­tracts, and growth in re­gional buses is de­clin­ing. A spate of con­tract losses is wor­ry­ing. Sell. 167p.

Stan­ley Gib­bons In­vestors Chron­i­cle

The trou­bled stamp and coin spe­cial­ist has suf­fered a 48% fall in as­set val­ues, a 28% de­cline in rev­enues and widen­ing losses. The com­pany is now in de­fault and de­pen­dent on its bank main­tain­ing sup­port. Sell. 7.8p.

WM Mor­ri­son Share­cast

Af­ter two years of “stel­lar ex­e­cu­tion” since David Potts be­came CEO, self-help and catch-up op­por­tu­ni­ties are now “more lim­ited” for the gro­cer. Beren­berg fears a slow-down in mo­men­tum could drive a de-rat­ing. Sell. 235.8p.

Newspapers in English

Newspapers from UK

© PressReader. All rights reserved.